Thalidomide to treat multiple myeloma

 

Few drugs, if any, have achieved the sad notoriety of thalidomide. Introduced in the late 1950s, it caused congenital birth defects in thousands of children worldwide and has been one of the most cautionary tales in the history of medicine. The medicine was banned at the beginning of the 1960s. During the years that followed, some beneficial effects of thalidomide were recognised for various disorders, and in Europe, since the ban, thalidomide has been used off-license and prescribed on a compassionate basis, mainly in hospitals.
 
In 2002, the European Medicines Agency (EMEA) received four marketing authorisation applications for thalidomide, which brought issues back to the surface. For the thalidomide victim associations, it was simply unacceptable that the drug be licensed again, and for the patient associations, it represented a major medical progress against their ailment.
 
As of 2006, however, no marketing applications had been authorised. Eurordis continued to work with all stakeholders to encourage marketing authorisation for thalidomide under strong safety guidelines.
 
For more information: Eurordis’ newsletter article - November 2006

 

 
 
La voz de los pacientes de enfermedades raras en EuropaEURORDIS La voz internacional de las personas que tienen enfermedades rarasRare Disease International Reuniendo a pacientes, familiares y expertos para compartir experiencias en un foro moderado en distintos idiomas. RareConnect El Programa Rare Barometer es una iniciativa de EURORDIS que realiza encuestas para transformar las experiencias de los pacientes con enfermedades raras en cifras que puedan compartirse con los responsables políticos.Rare Barometer Una campaña internacional de sensibilización que se celebra todos los años el último día de febrero, El Día de las Enfermedades Raras es una iniciativa de EURORDISRare Disease Day Únete al mayor grupo de partes interesadas en toda Europa, en la Conferencia Europea sobre Enfermedades Raras y Medicamentos Huérfanos que se celebra cada dos años. ECRD es una iniciativa de EURORDISEuropean Conference on Rare Diseases